Kestra Advisory Services’s Protalix BioTherapeutics PLX Stock Holding History

Kestra Advisory Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.6K	Hold	10,000	–	–	﹤0.01%	3409
2026 Q2	$23.3K	Hold	10,000	–	–	﹤0.01%	3234
2026 Q1	$21.7K	Hold	10,000	–	–	﹤0.01%	3092
2025 Q4	$18K	Sell	10,000 -1,000	-9%	-$2.04K	﹤0.01%	4520
2025 Q3	$24.4K	Buy	+11,000	New	+$17.9K	﹤0.01%	2878
2025 Q2	–	Sell	-44,500	Closed	-$114K	–	2951
2025 Q1	$114K	Buy	44,500 +30,500	+218%	+$72.8K	﹤0.01%	2573
2024 Q4	$26.3K	Sell	14,000 -2,000	-13%	-$2.83K	﹤0.01%	2633
2024 Q3	$16.3K	Hold	16,000	–	–	﹤0.01%	2536
2024 Q2	$18.7K	Hold	16,000	–	–	﹤0.01%	2591
2024 Q1	$20.2K	Buy	16,000 +4,500	+39%	+$6.72K	﹤0.01%	2430
2023 Q4	$20.5K	Hold	11,500	–	–	﹤0.01%	2246
2023 Q3	$19.1K	Hold	11,500	–	–	﹤0.01%	2083
2023 Q2	$23K	Buy	+11,500	New	+$27.4K	﹤0.01%	2075

Other funds holding PLX

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Kestra Advisory Services's PLX Position: Q3 2026 in Review

Kestra Advisory Services held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 10,000 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

Kestra Advisory Services first reported a position in PLX in Q2 2023 and has held it in 13 quarters since. The position peaked at $114K in Q1 2025. 22 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Kestra Advisory Services held 10,000 shares of Protalix BioTherapeutics worth $27.6K as of Q3 2026.
Kestra Advisory Services left its Protalix BioTherapeutics share count unchanged in Q3 2026.
Protalix BioTherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3409 holding.
Kestra Advisory Services first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 13 quarters since.
Kestra Advisory Services's Protalix BioTherapeutics position peaked at $114K in Q1 2025.
22 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.